Literature DB >> 9330946

Psychosocial factors associated with complementary treatment use in fibromyalgia.

P M Nicassio1, C Schuman, J Kim, A Cordova, M H Weisman.   

Abstract

OBJECTIVE: To examine the frequency and predictors of reported complementary treatment use in a sample of 111 subjects with fibromyalgia (FM). The perspective was adopted that complementary treatment use represents a form of medical help-seeking that may be subject to a variety of biological, social, and psychological influences.
METHODS: Patients with FM were recruited from community and university based clinics and support groups throughout the greater San Diego, California, area. Patients participated in a comprehensive evaluation of their pain, psychological functioning, and disability prior to their potential involvement in a clinical trial designed to help them copy with their condition. They were also administered a rheumatological evaluation to verify their FM and a 20 item questionnaire to assess their use of complementary treatment strategies specifically for coping with FM.
RESULTS: Ninety-eight percent of the sample reported the use of at least one strategy over the preceding 6 months. Exercise, bed rest, vitamins, heat treatment, and spirituality/praying were the most frequently used strategies by subjects on a daily basis. Multiple regression analysis revealed that lower age, higher pain, and higher disability were uniquely associated with higher complementary treatment use. The Pain Rating Index, a measure of the subjective severity of pain from the McGill Pain Questionnaire, proved highly significant in explaining the relationship between pain and questionnaire scores. Pain coping strategies and quality of social support did not predict complementary treatment use.
CONCLUSION: The findings suggest that poor clinical status is a major predictor of complementary treatment use in FM. However, longitudinal research is recommended to clarify the relationship between clinical status and help-seeking patterns in patients with FM over time.

Entities:  

Mesh:

Year:  1997        PMID: 9330946

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Sleep disturbance, inflammation and depression risk in cancer survivors.

Authors:  Michael R Irwin; Richard E Olmstead; Patricia A Ganz; Reina Haque
Journal:  Brain Behav Immun       Date:  2012-05-24       Impact factor: 7.217

2.  [Alternative and complementary therapies in fibromyalgia syndrome].

Authors:  J Langhorst; W Häuser; D Irnich; N Speeck; E Felde; A Winkelmann; H Lucius; A Michalsen; F Musial
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

3.  Use of complementary therapies and non-prescribed medication in patients with Parkinson's disease.

Authors:  P Ferry; M Johnson; P Wallis
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

4.  Use of complementary and alternative medicine providers by fibromyalgia patients under insurance coverage.

Authors:  Bonnie K Lind; William E Lafferty; Patrick Timothy Tyree; Paula K Diehr; David E Grembowski
Journal:  Arthritis Rheum       Date:  2007-02-15

5.  A parallel randomized controlled trial examining the effects of rhythmic sensory stimulation on fibromyalgia symptoms.

Authors:  Thenille Braun Janzen; Denise Paneduro; Larry Picard; Allan Gordon; Lee R Bartel
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

6.  Attitudes towards fibromyalgia: a survey of Canadian chiropractic, naturopathic, physical therapy and occupational therapy students.

Authors:  Jason W Busse; Abhaya V Kulkarni; Parminder Badwall; Gordon H Guyatt
Journal:  BMC Complement Altern Med       Date:  2008-05-31       Impact factor: 3.659

7.  Complementary and alternative medicine for the treatment of fibromyalgia.

Authors:  Jost Langhorst; Winfried Häuser; Romy Lauche; Serge Perrot; Cayetano Alegre; Piercarlo C Sarzi Puttini
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.